OT

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%
HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$50.00M
EPS-0.5200
P/E Ratio-2.73
Earnings Date03/30/2026

ostx

Net Change in Cash

Last Annual Value

5.49M

3-Year CAGR

89%

5-Year CAGR

-66%

10-Year CAGR

-42%

OT

OS Therapies Incorporated Competitors Analysis of Net Change in Cash

OSTX · NYSE
CompanyNet Change in Cash
CAGR 3Y
CAGR 5Y
CAGR 10Y
5.49M
N/AN/AN/A 
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
1.21M
-31.2%-42.3%N/A
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
-9.55M
N/AN/AN/A
-18.69M
N/AN/AN/A
4.68M
N/AN/A-5.8%
6.02M
N/AN/AN/A
-54.26M
N/AN/AN/A
10.15M
-47.9%N/AN/A
5.14M
N/A21.1%N/A
6.35M
N/A-24.4%N/A
-6844.45B
N/AN/AN/A
OT

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

Intrinsic Value
Current Price: $1.42